It’s crucial that life-saving medicines not be collateral damage of his trade war.
President Trump very recently signed an executive order exempting a range of products from his proposed tariffs, including some pharmaceuticals.
One day prior, he issued an order exempting generic pharmaceuticals from Japan from tariffs.
It’s encouraging news, to be sure — particularly for American patients. But policies which shield vital products such as medicines from trade barriers shouldn’t be the exception. They should be the norm.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
America Can’t Tariff Its Way to a Manufacturing Boom
Sally C. Pipes
It’s crucial that life-saving medicines not be collateral damage of his trade war.
President Trump very recently signed an executive order exempting a range of products from his proposed tariffs, including some pharmaceuticals.
One day prior, he issued an order exempting generic pharmaceuticals from Japan from tariffs.
It’s encouraging news, to be sure — particularly for American patients. But policies which shield vital products such as medicines from trade barriers shouldn’t be the exception. They should be the norm.
Read the op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.